For the quarter ending 2025-09-30, BGLC made $2,543,823 in revenue. -$705,775 in net income. Net profit margin of -27.74%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue (including 25,649 and 23,456 of revenue from related parties for the three months period ended september 30, 2025 and 2024 respectively, including 57,632 and 65,380 of revenue from related parties for the nine months period ended september 30, 2025 and 2024 respectively) | 2,543,823 | 2,260,253 | 2,137,075 | 2,630,376 |
| Cost of revenue (including 7,233 and 192,171 of cost of revenue from related parties for the three months period ended september 30, 2025 and 2024, respectively, including 9,404 and 293,770 of cost of revenue from related parties for the nine months period ended ended september 30, 2025 and 2024, respectively) | 2,166,138 | 1,892,231 | 1,793,582 | 2,303,840 |
| Gross profit | 377,685 | 368,022 | 343,493 | 326,536 |
| Dividend income | 4,192 | 8,626 | 8,934 | - |
| Interest income | 20,778 | 29,768 | 23,568 | - |
| Fair value gain on investments in equity securities | 0 | 23,742 | 4,514 | - |
| Gain on disposal of investments in equity securities | 42,376 | 0 | - | - |
| Reversal of expected credit losses | 0 | 69,759 | 25,153 | - |
| Others | 40,414 | 77,566 | 29,251 | 465,527 |
| Total other income | 107,760 | 209,461 | 91,420 | - |
| Sales and marketing | 551,569 | 608,427 | - | - |
| Research and development | 14,876 | 12,557 | - | - |
| General and administrative (including 1,065 and 1,006 of rental expenses to related party for the three months period ended september 30, 2025 and 2024, respectively, including 3,156 and 1,006 of rental expenses to related party for the nine months period ended september 30, 2025 and 2024, respectively) | 445,691 | 516,790 | - | 2,129,685 |
| Fair value loss on investments in equity securities | 0 | 51,002 | - | - |
| Provision for expected credit losses | 175,818 | 0 | - | - |
| Total operating expenses | 1,187,954 | 1,188,776 | -1,053,331 | - |
| Loss from operations | -702,509 | -611,293 | -618,418 | -1,337,622 |
| Interest expense, operating and nonoperating | - | - | - | 6,193 |
| Finance costs | 6,482 | 4,879 | 4,909 | - |
| Loss before tax | -708,991 | -616,172 | -623,327 | -1,343,815 |
| Tax expense | 0 | 0 | - | 1,555 |
| Net loss attributable to common shareholders | -708,991 | -616,172 | -623,327 | -1,345,370 |
| Foreign currency translation gain/(loss) | - | - | 72,159 | 1,046,789 |
| Foreign currency translation gain | 3,216 | 367,078 | - | - |
| Comprehensive loss | -705,775 | -249,094 | -551,168 | -298,581 |
| Basic & diluted eps | - | - | - | -0.017 |
| Earnings per share - basic and diluted | -0.395 | -0.343 | -0.035 | - |
| Weighted average number of common stocks outstanding, basic and diluted | 1,796,597 | 1,796,597 | 17,967,663 | - |
BioNexus Gene Lab Corp (BGLC)
BioNexus Gene Lab Corp (BGLC)